Pacific Edge will benefit from increased margins on select Cxbladder cancer diagnostic tests due to a proposed Medicare price rise in the United States.
- Pacific Edge is a dual-listed cancer diagnostics company.
- The company’s Cxbladder tests are utilized for bladder cancer diagnostics.
- The Medicare price increase applies specifically to some of these Cxbladder tests.
- Pacific Edge has won its first blanket purchase agreement within the US Veterans Administration.
Why it matters
Higher margins on tests reimbursed through Medicare and a contract with the US Veterans Administration improve revenue stability and financial outlook, which may affect procurement decisions and partnership negotiations for SMEs offering diagnostic services or working in related healthcare sectors.
Source: NBR
← All news
